1. Home
  2. SRPT vs REGCO Comparison

SRPT vs REGCO Comparison

Compare SRPT & REGCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sarepta Therapeutics Inc. (DE)

SRPT

Sarepta Therapeutics Inc. (DE)

HOLD

Current Price

$21.30

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Logo Regency Centers Corporation 5.875% Series B Cumulative Redeemable Preferred Stock

REGCO

Regency Centers Corporation 5.875% Series B Cumulative Redeemable Preferred Stock

N/A

Current Price

$22.17

Market Cap

0.0

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SRPT
REGCO
Founded
1980
N/A
Country
United States
United States
Employees
N/A
500
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
N/A
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
SRPT
REGCO
Price
$21.30
$22.17
Analyst Decision
Hold
Analyst Count
29
0
Target Price
$25.85
N/A
AVG Volume (30 Days)
3.3M
4.6K
Earning Date
05-05-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,198,237,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
15.58
N/A
52 Week Low
$10.42
$21.35
52 Week High
$64.80
$24.24

Technical Indicators

Market Signals
Indicator
SRPT
REGCO
Relative Strength Index (RSI) 53.50 49.08
Support Level $20.61 $22.12
Resistance Level $23.25 $22.99
Average True Range (ATR) 1.11 0.23
MACD -0.16 0.03
Stochastic Oscillator 18.43 21.34

Price Performance

Historical Comparison
SRPT
REGCO

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.

About REGCO Regency Centers Corporation 5.875% Series B Cumulative Redeemable Preferred Stock

Regency Centers is one of the largest shopping center-focused retail REITs. The company's portfolio includes an interest in 483 properties, which includes over 57 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.

Share on Social Networks: